Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | — | — | 2 | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | — | — | 2 | — | — | 2 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | — | — | 2 | — | — | 2 |
Squamous cell carcinoma | D002294 | — | — | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | — | 5 |
Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Feladilimab |
INN | feladilimab |
Description | Feladilimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target inducible T-cell costimulator. |
Classification | Antibody |
Drug class | vasodilators (undefined group); monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4297969 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | OUP4QB2A3R (ChemIDplus, GSRS) |